Trial Profile
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination With Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2020
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary) ; Letrozole
- Indications Advanced breast cancer; Menopause
- Focus Registrational; Therapeutic Use
- Acronyms HORIZON
- Sponsors Wyeth
- 26 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 11 Aug 2005 New trial record.